Cantheon Capital

Oxford Cannabinoid Technologies Ltd. is a biopharmaceutical company based in Oxford, United Kingdom, dedicated to the research and development of cannabinoid-based compounds and therapies. Established in 2017, the company aims to address various medical conditions, including inflammatory diseases, oncology, neurological disorders, and pain management. It employs a drug development approach that incorporates proprietary cannabinoid derivatives, natural phytocannabinoids, and in-licensed compounds. The company's primary focus is on the pain market, with plans to develop a portfolio of drug candidates intended for regulatory approval as licensed pain medications, all while collaborating with leading medical researchers to meet high unmet medical needs.

Psycheceutical specializes in developing advanced delivery technologies for psychedelic pharmaceuticals, focusing on safety and efficacy. By utilizing patented Janus particles and innovative delivery systems, the company aims to ensure precise dosage control and consistent therapeutic outcomes for patients. Their technology enables the targeted delivery of psychedelic compounds directly to specific cells, which is particularly beneficial for treating conditions such as liver diseases while minimizing associated toxicity. Psycheceutical's approach seeks to transform conventional treatment methods and enhance patient care in the medical and pharmaceutical sectors.

Albert Labs is a biopharmaceutical company dedicated to developing innovative prescription medicines for patients with unmet mental health needs. The company employs advanced culture technology and natural extraction methods, complemented by a thorough regulatory approach, to expedite the development of mental health drugs. Albert Labs focuses on utilizing Real World Evidence (RWE) as a clinical pathway, which has been effectively used in oncology and the rapid development of COVID-19 vaccines. Initially, the company aims to commercialize its mycelium-based treatment, KRN-101, leveraging RWE to address critical mental health care requirements.

Psyence is a life science biotechnology company dedicated to the research, cultivation, and production of natural psilocybin and other nature-based compounds aimed at addressing psychological trauma and related disorders such as anxiety, depression, PTSD, and stress. The company emphasizes the application of these substances within palliative care settings to enhance mental wellness. Psyence engages in scientific research and development of psilocybin medical products for clinics and research institutions, ensuring regulatory compliance. Additionally, it is developing functional mushroom nutraceuticals that target depression, anxiety, and sleep disorders.

Zelira Therapeutics Limited is a bio-pharmaceutical company based in Perth, Australia, specializing in the development of cannabinoid-based formulations aimed at treating various medical conditions. The company conducts human clinical trials targeting insomnia, autism, and opioid reduction, while also engaging in pre-clinical research to explore the effects of cannabinoids on breast, brain, and pancreatic cancers. Additionally, Zelira is investigating the potential of cannabinoid formulations to address diabetes-associated cognitive decline. The company collaborates with CannPal Pty Ltd and St Vincent's Hospital on opioid reduction studies. Formerly known as Zelda Therapeutics Limited, it rebranded to Zelira Therapeutics Limited in December 2019.